Highest development stage: Phase 3

Development status: Active (as of 2022)

Gram-positive activity

Gram-negative activity

Mechanism of Action/Target pathogen: Binds to bacterial penicillin-binding proteins and interferes with bacterial cell wall integrity and synthesis. Less active than carbapenems against Gram-negative bacteria, no activity against Pseudomonas aeruginosa

Additional information: Synthetic compound, fixed combination with probenicid. Oral and iv formulation,not non-inferior to ertapenem in a Phase 3 clinical study in complicated intraabdominal infections and not non-inferior to ciprofloxacin in treatment of uUTI